# Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients

> **NCT00417911** · PHASE3 · COMPLETED · sponsor: **Nordic Myeloma Study Group** · enrollment: 400 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT00417911
- **Lead sponsor:** Nordic Myeloma Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2009-05
- **Final completion:** 2010-05
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2010-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00417911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00417911, "Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00417911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*